• 1
    Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964967.
  • 2
    Kalka C, Masuda H, Takahashi T et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000;97:34223427.
  • 3
    Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430436.
  • 4
    Murohara T, Ikeda H, Duan J et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest 2000;105:15271536.
  • 5
    Ormiston ML, Deng Y, Stewart DJ et al. Innate immunity in the therapeutic actions of endothelial progenitor cells in pulmonary hypertension. Am J Respir Cell Mol Biol 2010;43:546554.
  • 6
    Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: Part II: Cell-based therapies. Circulation 2004;109:26922697.
  • 7
    Aicher A, Brenner W, Zuhayra M et al. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation 2003;107:21342139.
  • 8
    Bi B, Schmitt R, Israilova M et al. Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol 2007;18:24862496.
  • 9
    Gnecchi M, He H, Liang OD et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005;11:367368.
  • 10
    Mirotsou M, Jayawardena TM, Schmeckpeper J et al. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol 2011;50:280289.
  • 11
    Yuen DA, Connelly KA, Advani A et al. Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism. Plos One 2010;5:e9543.
  • 12
    Zhang Y, Yuen DA, Advani A et al. Early-outgrowth bone marrow cells attenuate renal injury and dysfunction via an antioxidant effect in a mouse model of type 2 diabetes. Diabetes 2012;61:21142125.
  • 13
    Nagy A, Quaggin SE. Stem cell therapy for the kidney: A cautionary tale. J Am Soc Nephrol 2010;21:10701072.
  • 14
    Thirabanjasak D, Tantiwongse K, Thorner PS. Angiomyeloproliferative lesions following autologous stem cell therapy. J Am Soc Nephrol 2010;21:12181222.
  • 15
    Parfrey PS, Harnett JD, Barre PE. The natural history of myocardial disease in dialysis patients. J Am Soc Nephrol 1991;2:212.
  • 16
    Ortiz LA, Gambelli F, McBride C et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003;100:84078411.
  • 17
    Yuen DA, Zhang Y, Thai K et al. Angiogenic dysfunction in bone marrow-derived early outgrowth cells from diabetic animals is attenuated by SIRT1 activation. Stem Cells Transl Med 2012;1:921926.
  • 18
    Lee CH, Shah B, Moioli EK et al. CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model. J Clin Invest 2010;120:33403349.
  • 19
    Gnecchi M, Zhang Z, Ni A et al. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008;103:12041219.
  • 20
    Ku CH, Johnson PH, Batten P et al. Collagen synthesis by mesenchymal stem cells and aortic valve interstitial cells in response to mechanical stretch. Cardiovasc Res 2006;71:548556.
  • 21
    Rhaleb NE, Peng H, Harding P et al. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension 2001;37:827832.
  • 22
    Advani A, Gilbert RE, Thai K et al. Expression, localization, and function of the thioredoxin system in diabetic nephropathy. J Am Soc Nephrol 2009;20:730741.
  • 23
    Martin J, Kelly DJ, Mifsud SA et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: Role of transforming growth factor-beta. Cardiovasc Res 2005;65:694701.
  • 24
    Advani A, Kelly DJ, Advani SL et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci USA 2007;104:1444814453.
  • 25
    Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002;99:89328937.
  • 26
    Connelly KA, Prior DL, Kelly DJ et al. Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: A comparison with load-insensitive measures. Am J Physiol Heart Circ Physiol 2006;290:H1699H1705.
  • 27
    Kelly DJ, Chanty A, Gow RM et al. Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol 2005;16:16541660.
  • 28
    Batruch I, Lecker I, Kagedan D et al. Proteomic analysis of seminal plasma from normal volunteers and post-vasectomy patients identifies over 2000 proteins and candidate biomarkers of the urogenital system. J Proteome Res 2011;10:941953.
  • 29
    Llevadot J, Murasawa S, Kureishi Y et al. HMG-CoA reductase inhibitor mobilizes bone marrow–derived endothelial progenitor cells. J Clin Invest 2001;108:399405.
  • 30
    Teraa M, Sprengers RW, Westerweel PE et al. Bone marrow alterations and lower endothelial progenitor cell numbers in critical limb ischemia patients. Plos One 2013;8:e55592.
  • 31
    Yoder MC, Mead LE, Prater D et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007;109:18011809.
  • 32
    van Koppen A, Joles JA, van Balkom BW et al. Human embryonic mesenchymal stem cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease. Plos One 2012;7:e38746.
  • 33
    Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315317.
  • 34
    Bohle A, Mackensen-Haen S, von Gise H. Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: A morphometric contribution. Am J Nephrol 1987;7:421433.
  • 35
    Pula G, Mayr U, Evans C et al. Proteomics identifies thymidine phosphorylase as a key regulator of the angiogenic potential of colony-forming units and endothelial progenitor cell cultures. Circ Res 2009;104:3240.
  • 36
    Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:S112119.
  • 37
    Kumar AH, Caplice NM. Clinical potential of adult vascular progenitor cells. Arterioscler Thromb Vasc Biol 2010;30:10801087.
  • 38
    Gnecchi M, He H, Noiseux N et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006;20:661669.
  • 39
    Di Santo S, Yang Z, Wyler von Ballmoos M et al. Novel cell-free strategy for therapeutic angiogenesis: In vitro generated conditioned medium can replace progenitor cell transplantation. Plos One 2009;4:e5643.
  • 40
    Abdel-Latif A, Bolli R, Tleyjeh IM et al. Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis. Arch Intern Med 2007;167:989997.
  • 41
    Ibbotson KJ, D'Souza SM, Ng KW et al. Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science 1983;221:12921294.
  • 42
    Rosenzweig A. Cardiac cell therapy–mixed results from mixed cells. N Engl J Med 2006;355:12741277.